Ergomed ( ) - 株価, ニュースと分析AIM:ERGO

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

ERGO 株式概要

Ergomed plc, together with its subsidiaries, provides clinical trial planning, management, and monitoring; and drug safety and medical information services in the United Kingdom, rest of Europe, the Middle East, Africa, North America, and internationally.

会社概要

ERGO ファンダメンタル分析
スノーフレーク・スコア
評価	0/6
将来の成長	3/6
過去の実績	3/6
財務の健全性	6/6
配当金	0/6

報酬

収益は年間14.17%増加すると予測されています

過去1年間で収益は12.3%増加しました

リスク分析

過去3か月間の株価の変動

過去1年間で株主の希薄化が進んだ

Ergomed plc 競合他社

hVIVO

AIM:HVO

UK£192.9m

C4X Discovery Holdings

AIM:C4XD

UK£30.3m

Genus

LSE:GNS

UK£1.3b

Bioventix

AIM:BVXP

UK£198.3m

価格と性能

の歴代最高値、変動、値下がりまとめErgomed
過去の株価
現在の株価	UK£13.46
52週高値	UK£13.80
52週安値	UK£8.95
ベータ	0.79
11ヶ月の変化	0.90%
3ヶ月変化	21.26%
1年変化	3.54%
33年間の変化	67.41%
5年間の変化	812.54%
IPOからの変化	728.31%

Recent updates

If You Had Bought Ergomed (LON:ERGO) Stock Five Years Ago, You Could Pocket A 643% Gain Today

Feb 22

Has Ergomed plc's (LON:ERGO) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Jan 18

Ergomed plc's (LON:ERGO) Intrinsic Value Is Potentially 20% Below Its Share Price

Dec 13

We Think Ergomed's (LON:ERGO) Statutory Profit Might Understate Its Earnings Potential

Nov 23

株主還元

	ERGO	GB Life Sciences	GB 市場
7D	0.1%	-1.0%	1.4%
1Y	3.5%	-16.3%	8.1%

業界別リターン: ERGO過去 1 年間で-40.3 % の収益を上げたUK Life Sciences業界を上回りました。

リターン対市場: ERGO過去 1 年間で5.4 % の収益を上げたUK市場を上回りました。

価格変動

Is ERGO's price volatile compared to industry and market?
ERGO volatility
ERGO Average Weekly Movement	8.1%
Life Sciences Industry Average Movement	7.2%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	9.5%
10% least volatile stocks in GB Market	2.5%

安定した株価: ERGOの株価は過去 3 か月間にわたって変動しています。

時間の経過による変動: ERGOの weekly volatility ( 8% ) は過去 1 年間安定していますが、依然としてUKの株式の 75% よりも高くなっています。

会社概要

設立	従業員	CEO（最高経営責任者	ウェブサイト
1997	1,400	n/a	www.ergomedplc.com

Ergomed plc 基礎のまとめ

Ergomed の収益と売上を時価総額と比較するとどうか。
ERGO 基礎統計学
時価総額	UK£701.05m
収益（TTM）	UK£15.00m
売上高(TTM)	UK£152.09m

46.7x

PER（株価収益率

4.6x

P/Sレシオ

ERGO は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
ERGO 損益計算書（TTM）
収益	UK£152.09m
売上原価	UK£68.82m
売上総利益	UK£83.27m
その他の費用	UK£68.27m
収益	UK£15.00m

直近の収益報告

Jun 30, 2023

次回決算日

該当なし

一株当たり利益（EPS）	0.29
グロス・マージン	54.75%
純利益率	9.86%
有利子負債／自己資本比率	0%

ERGO の長期的なパフォーマンスは？

過去の実績と比較を見る

ERGO 株式概要

報酬

リスク分析

Ergomed plc 競合他社

AIM:HVO

UK£192.9m

AIM:C4XD

UK£30.3m

LSE:GNS

UK£1.3b

AIM:BVXP

UK£198.3m

価格と性能

最新ニュース

Ergomed Submits an Application London Stock Exchange in Relation to the Cancellation of the Admission to Trading of its Shares on AIM, Expects to Take Place on 14 November 2023

Permira Advisers Ltd. completed the acquisition of Ergomed plc (AIM:ERGO) from Amati Global Investors Ltd. and others.

Ergomed Confirms Expected Scheme Timetable

Ergomed plc (AIM:ERGO) acquired Panacea Pharma Projects Limited from Stuart Colligon.

Permira Advisers Ltd. entered into a scheme of arrangement to acquire Ergomed plc (AIM:ERGO) from Amati Global Investors Ltd. and others for approximately £700 million.

Ergomed plc to Report Q2, 2023 Results on Sep 26, 2023

Recent updates

Ergomed Submits an Application London Stock Exchange in Relation to the Cancellation of the Admission to Trading of its Shares on AIM, Expects to Take Place on 14 November 2023

Permira Advisers Ltd. completed the acquisition of Ergomed plc (AIM:ERGO) from Amati Global Investors Ltd. and others.

Ergomed Confirms Expected Scheme Timetable

Ergomed plc (AIM:ERGO) acquired Panacea Pharma Projects Limited from Stuart Colligon.

Permira Advisers Ltd. entered into a scheme of arrangement to acquire Ergomed plc (AIM:ERGO) from Amati Global Investors Ltd. and others for approximately £700 million.

Ergomed plc to Report Q2, 2023 Results on Sep 26, 2023

Now 20% undervalued after recent price drop

Is It Time To Consider Buying Ergomed plc (LON:ERGO)?

Ergomed plc Provides Earnings Forecast for the Full Year 2023

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Ergomed plc, Annual General Meeting, Jun 22, 2023

At UK£9.74, Is Ergomed plc (LON:ERGO) Worth Looking At Closely?

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new and inexperienced directors

Ergomed plc to Report Fiscal Year 2022 Results on Mar 21, 2023

High number of new and inexperienced directors

Ergomed plc Announces Board Changes, Effective 3 February 2023

Ergomed plc Announces Executive Changes

Ergomed plc Announces Directorate Changes

Ergomed Announces Two Senior Appointments to its Executive Team

Ergomed Strengthens Executive Management Team

Ergomed Strengthens Executive Management Team

Ergomed plc (LON:ERGO) Shares Could Be 21% Below Their Intrinsic Value Estimate

First half 2022 earnings released: EPS: UK£0.15 (vs UK£0.14 in 1H 2021)

Ergomed plc to Report First Half, 2022 Results on Sep 27, 2022

Investor sentiment improved over the past week

Should You Be Adding Ergomed (LON:ERGO) To Your Watchlist Today?

Why Ergomed plc (LON:ERGO) Could Be Worth Watching

Ergomed plc Appoints Anne Whitaker as Independent Non-Executive Director

Full year 2021 earnings: EPS misses analyst expectations

Ergomed plc, Annual General Meeting, Jun 10, 2022

Consensus EPS estimates increase by 11%

Consensus forecasts updated

Less than half of directors are independent

Now 21% undervalued

Calculating The Fair Value Of Ergomed plc (LON:ERGO)

Full year 2021 earnings: EPS misses analyst expectations

Does Ergomed (LON:ERGO) Deserve A Spot On Your Watchlist?

John Dawson, Cbe Joins the Board of Ergomed plc as Independent Non-Executive Director and Chair of the Audit Committee

Why Ergomed plc (LON:ERGO) Could Be Worth Watching

Ergomed plc to Report Fiscal Year 2021 Results on Mar 29, 2022

Pharmaust Limited Engages Ergomed Clinical Research Ltd to Commence Clinical Trials Testing the Anti-Viral Effects of Monepantel

Ergomed plc (AIM:ERGO) acquired Adamas Consulting Ltd. at an enterprise value of £24.2 million.

Ergomed plc Provides Revenue Guidance for the Year Ended 31 December 2021

Investor sentiment deteriorated over the past week

Calculating The Fair Value Of Ergomed plc (LON:ERGO)

Investor sentiment improved over the past week

I Ran A Stock Scan For Earnings Growth And Ergomed (LON:ERGO) Passed With Ease

First half 2021 earnings released: EPS UK£0.14 (vs UK£0.089 in 1H 2020)

Calculating The Intrinsic Value Of Ergomed plc (LON:ERGO)

Investor sentiment improved over the past week

If You Like EPS Growth Then Check Out Ergomed (LON:ERGO) Before It's Too Late

Getting In Cheap On Ergomed plc (LON:ERGO) Might Be Difficult

Ergomed plc (LON:ERGO) Shares Could Be 31% Above Their Intrinsic Value Estimate

Price target increased to UK£13.65

Non-Executive Director has left the company

Investor sentiment improved over the past week

Do Ergomed's (LON:ERGO) Earnings Warrant Your Attention?

Full year 2020 earnings released